Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Dipyridyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | CCR1 | P32246 | 3/20 | 0.93 |
| ▸ | CCR5 | P51681 | 3/20 | 0.93 |
| ▸ | CCR8 | P51685 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.93 |
| ▸ | POLB | P06746 | 1/20 | 0.93 |
| ▸ | METAP1 | P53582 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.93 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.93 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.93 |
| ▸ | NPC1 | O15118 | 6/20 | 0.74 |
| ▸ | TP53 | P04637 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyridyl SCHEMBL15136892 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL3799914 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL2371023 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL18065641 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL497901 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL8716183 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL7909040 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL6749371 | 0.97 | KDM4E (0.88) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL28482248 | 0.97 | KDM4E (0.88) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29115681 | 0.97 | KDM4E (0.88) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108794432-B | Method for preparing gamma lactone by photosensitization catalysis | 山东新和成药业有限公司 | 2020-04-21 | — | — | CN | claimed |
| EP-1192448-B1 | PROCESS OF USING A SENSOR PLATFORM | NOVARTIS AG (CH) | 2006-09-27 | — | — | EP | claimed |
| US-6771376-B2 | ANALYSING SAMPLES, AFFINITY SENSING, DNA, PROTEIN, PEPTIDE AND ANTIBODY CHIP TECHNOLOGY | NOVARTIS AG (CH) | 2004-08-03 | — | — | US | claimed |
| US-20040115825-A1 | Substrate with thin, optical transparent layer; variations in refractive index; corrugated structure | BUDACH WOLFGANG ERNST GUSTAV (DE) | 2004-06-17 | — | — | US | claimed |
| US-20040115826-A1 | Detector on substrate; variations in refractive index | BUDACH WOLFGANG ERNST GUSTAV (DE) | 2004-06-17 | — | — | US | claimed |
| US-6469785-B1 | Optical detection device based on semi-conductor laser array | ZEPTOSENS AG (CH) | 2002-10-22 | — | — | US | claimed |
| US-20020135780-A1 | Sensor platform, apparatus incorporating the platform, and process using the platform | NOVARTIS AG (CH) | 2002-09-26 | — | — | US | claimed |
| EP-1192448-A1 | SENSOR PLATFORM, APPARATUS INCORPORATING THE PLATFORM, AND PROCESS USING THE PLATFORM | Novartis AG (CH) | 2002-04-03 | — | — | EP | claimed |
| WO-2001002839-A1 | SENSOR PLATFORM, APPARATUS INCORPORATING THE PLATFORM, AND PROCESS USING THE PLATFORM | NOVARTIS AG (CH) | 2001-01-11 | — | — | WO | claimed |
| EP-0918984-A1 | OPTICAL DETECTOR | Novartis AG (CH) | 1999-06-02 | — | — | EP | claimed |
| WO-1998008077-A1 | OPTICAL DETECTOR | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | claimed |
| EP-0824684-A1 | SENSOR PLATFORM AND METHOD FOR THE PARALLEL DETECTION OF A PLURALITY OF ANALYTES USING EVANESCENTLY EXCITED LUMINESCENCE | Novartis AG (CH) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035940-A1 | SENSOR PLATFORM AND METHOD FOR THE PARALLEL DETECTION OF A PLURALITY OF ANALYTES USING EVANESCENTLY EXCITED LUMINESCENCE | NOVARTIS AG (CH) | 1996-11-14 | — | — | WO | claimed |
| WO-2025233239-A1 | PROCESSES FOR PRODUCING OPTICAL EFFECT LAYERS | SICPA HOLDING SA (CH) | 2025-11-13 | — | — | WO | disclosed |
| US-11926697-B2 | Fluorine-containing liquid crystal elastomer and preparation method and use thereof | SOOCHOW UNIVERSITY (CN) | 2024-03-12 | — | — | US | disclosed |
| US-20220119589-A1 | FLUORINE-CONTAINING LIQUID CRYSTAL ELASTOMER AND PREPARATION METHOD AND USE THEREOF | SOOCHOW UNIVERSITY (CN) | 2022-04-21 | — | — | US | disclosed |
| WO-1996035940-A1 | SENSOR PLATFORM AND METHOD FOR THE PARALLEL DETECTION OF A PLURALITY OF ANALYTES USING EVANESCENTLY EXCITED LUMINESCENCE | NOVARTIS AG (CH) | 1996-11-14 | — | — | WO | disclosed |
| WO-1995033197-A1 | PROCESS FOR DETECTING EVANESCENTLY EXCITED LUMINESCENCE | CIBA-GEIGY AG (CH) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995033198-A1 | PROCESS FOR DETECTING EVANESCENTLY EXCITED LUMINESCENCE | CIBA-GEIGY AG (CH) | 1995-12-07 | — | — | WO | disclosed |
| WO-1993014104-A1 | PHOTOCLEAVAGE OF DNA USING ORGANIC OXYRADICALS | EASTMAN KODAK COMPANY (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119589-A1 | FLUORINE-CONTAINING LIQUID CRYSTAL ELASTOMER AND PREPARATION METHOD AND USE THEREOF | PFN1, FSCN1, FLNA | KDM4E 2323/4885LMNA 1157/4885CCR1 748/4885 |
| US-11926697-B2 | Fluorine-containing liquid crystal elastomer and preparation method and use thereof | PFN1, FSCN1, FLNA | KDM4E 2323/4885LMNA 1157/4885CCR1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.